Business
Fast Food Meal of French Fries, Burger, and Soda
Getty Images
Veg out

Like most Americans, McDonald’s has given up on Beyond Meat

The McPlant is dead, long live the $5 deal

Tom Jones, David Crowther

Unplanted

McDonald’s will likely be meat-free-free in America for the foreseeable future, after the company confirmed at a WSJ forum on Wednesday that the McPlant, a burger made in collaboration with Beyond Meat, failed when it was rolled out in hundreds of locations across California and Texas in 2022.

That’s a sizable setback for Beyond, which, despite some serious hype around the brand in earlier years, has never turned a profit and has seen its stock drop ~90% from its 2019 IPO. In its latest quarter, the plant-based producer reported net revenues that sunk 18% to $76M, the company’s 8th quarter of shrinking sales in a row.

Beyond Meat

Beyond’s been shouting about its grill-friendly Beyond IV range of burgers and sausages recently, but all anyone else has been talking about is how cooked the brand itself is. Growing concerns around processed food and waning veggie and vegan communities could explain Beyond’s decline in the past few years. Whatever the reason, when consumers stood in a McDonald’s and were given the choice between a beef burger and a Beyond burger, not enough people chose the latter.

Beyond America

The fake meat co’s fortunes have looked healthier overseas in recent years, with sales in Beyond Meat’s “International” division growing 20% in 2023 compared to the year before. Interestingly, the McPlant is still available across European nations like Germany, the UK, and the Netherlands. However, it appears that America’s meat-free malaise might be starting to spread, with overseas sales down 22% in the first quarter of 2024, which was more extreme than the 16% dropoff seen in the states.

Joe Erlinger, the McDonald’s USA president, told the WSJ’s Global Food Forum that he doesn’t think “the US consumer is coming to McDonald’s for the McPlant or other plant based proteins” — if Beyond’s sales are anything to go by, they’re not going direct to source either.

More Business

See all Business
The Sphere In Las Vegas

Washington D.C. looks set to get America’s second Sphere

Revenue for the Las Vegas version of the big orb has soared, but the sphere is still a money pit.

business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.